<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02265913</url>
  </required_header>
  <id_info>
    <org_study_id>PRG-NY-14-008</org_study_id>
    <nct_id>NCT02265913</nct_id>
  </id_info>
  <brief_title>Comparative Safety and Efficacy of Two Antiviral Treatments in the Treatment of Recurrent Herpes Simplex Labialis</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Padagis LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Padagis LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare safety and efficacy of Perrigo's antiviral drug product compared to an FDA&#xD;
      approved antiviral drug product in the treatment of cold sores.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 6, 2014</start_date>
  <completion_date type="Actual">November 21, 2017</completion_date>
  <primary_completion_date type="Actual">April 27, 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Lesion Healing</measure>
    <time_frame>up to 21 days</time_frame>
    <description>Time to complete healing of lesions measured in hours from the time of first dosing</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">4076</enrollment>
  <condition>Herpes Labialis</condition>
  <arm_group>
    <arm_group_label>Test Product</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>acyclovir cream</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference Product</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>acyclovir cream</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Product</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo cream</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acyclovir 5 percent (Perrigo)</intervention_name>
    <arm_group_label>Test Product</arm_group_label>
    <other_name>Perrigo product</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acyclovir 5 percent (Reference)</intervention_name>
    <arm_group_label>Reference Product</arm_group_label>
    <other_name>Reference Listed Drug Product</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo cream</intervention_name>
    <arm_group_label>Placebo Product</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Provides written informed consent/assent&#xD;
&#xD;
          2. Immunocompetent male or non-pregnant females, &gt;12 years old, with limited,&#xD;
             non-life-threatening, recurrent herpes simplex labialis.&#xD;
&#xD;
          3. Subjects must have at least 3 recurrences of herpes simplex labialis per year for the&#xD;
             past two years.&#xD;
&#xD;
          4. Females of childbearing potential willing to use an acceptable form of birth control.&#xD;
&#xD;
          5. Subjects must be in general good health with no clinically significant disease that&#xD;
             might interfere with the study evaluations in the opinion of the investigator.&#xD;
&#xD;
          6. Subjects must be willing and able to understand and comply with the requirements of&#xD;
             the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Females who are pregnant or nursing, are not using or does not agree to use an&#xD;
             acceptable form of contraception during the study, or who intends to become pregnant&#xD;
             during the study.&#xD;
&#xD;
          2. The use of antiviral therapies in various forms for a given period of time prior to&#xD;
             screening and study medication application.&#xD;
&#xD;
          3. Candidate for or previous use of parenteral antiviral treatment or prophylactic&#xD;
             antiviral therapy for their recurrent herpes simplex labialis.&#xD;
&#xD;
          4. Recently received an organ transplant.&#xD;
&#xD;
          5. Subjects who are immunocompromised, HIV positive or who have any immune-system&#xD;
             disorders.&#xD;
&#xD;
          6. Recent major change in immune system status that could seriously affect the clinical&#xD;
             manifestations of herpes simplex labialis and need for treatment in the opinion of the&#xD;
             investigator.&#xD;
&#xD;
          7. Subjects with known or suspected history of a clinically significant systemic disease,&#xD;
             unstable medical disorders, life-threatening disease or current malignancies.&#xD;
&#xD;
          8. Subjects with a current episode of herpes simplex labialis that has not completely&#xD;
             healed.&#xD;
&#xD;
          9. Presence of any facial skin condition or excessive facial hair that may interfere with&#xD;
             diagnosis, assessment, and/or healing ability.&#xD;
&#xD;
         10. History of herpes keratitis.&#xD;
&#xD;
         11. Subject has a history of hypersensitivity or allergy to any ingredient in the drug&#xD;
             product.&#xD;
&#xD;
         12. History of unresponsiveness to topical acyclovir therapy.&#xD;
&#xD;
         13. Participation in any other clinical study or who have received treatment with any&#xD;
             investigational drug or device within 30 days prior to screening.&#xD;
&#xD;
         14. Subjects who have previously enrolled in this study.&#xD;
&#xD;
         15. Subjects who have received any local medication in the target area during the 2 weeks&#xD;
             prior to both enrollment/screening and Day 1 (Visit 2).&#xD;
&#xD;
         16. Subjects who have been treated with immunosuppressive medication therapy within 8&#xD;
             weeks prior to the study both enrollment/screening and Day 1 (Visit 2).&#xD;
&#xD;
         17. Subject consumes excessive alcohol, abuses drugs, or has a condition that could&#xD;
             compromise the subject's ability to comply with study requirements in the&#xD;
             investigator's opinion.&#xD;
&#xD;
         18. Use of tanning booths, sun lamps, or excessive exposure to the sun for up to 21 days&#xD;
             from initiating study medication&#xD;
&#xD;
         19. Subjects using immunostimulators, dye-light therapy, or psoralen therapy within 30&#xD;
             days prior to study medication initiation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Quality Clinical Research Inc</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 10, 2014</study_first_submitted>
  <study_first_submitted_qc>October 15, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 16, 2014</study_first_posted>
  <results_first_submitted>October 26, 2020</results_first_submitted>
  <results_first_submitted_qc>December 9, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">January 5, 2021</results_first_posted>
  <disposition_first_submitted>June 27, 2016</disposition_first_submitted>
  <disposition_first_submitted_qc>June 27, 2016</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">June 29, 2016</disposition_first_posted>
  <last_update_submitted>October 20, 2021</last_update_submitted>
  <last_update_submitted_qc>October 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Herpes Labialis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acyclovir</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 22, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/13/NCT02265913/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 22, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/13/NCT02265913/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Test Product</title>
          <description>acyclovir cream&#xD;
Acyclovir 5 percent (Perrigo)</description>
        </group>
        <group group_id="P2">
          <title>Reference Product</title>
          <description>acyclovir cream&#xD;
Acyclovir 5 percent (Reference)</description>
        </group>
        <group group_id="P3">
          <title>Placebo Product</title>
          <description>Placebo cream&#xD;
Placebo cream</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1357"/>
                <participants group_id="P2" count="1361"/>
                <participants group_id="P3" count="1358"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="793"/>
                <participants group_id="P2" count="810"/>
                <participants group_id="P3" count="813"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="564"/>
                <participants group_id="P2" count="551"/>
                <participants group_id="P3" count="545"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Test Product</title>
          <description>acyclovir cream&#xD;
Acyclovir 5 percent (Perrigo)</description>
        </group>
        <group group_id="B2">
          <title>Reference Product</title>
          <description>acyclovir cream&#xD;
Acyclovir 5 percent (Reference)</description>
        </group>
        <group group_id="B3">
          <title>Placebo Product</title>
          <description>Placebo cream&#xD;
Placebo cream</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1357"/>
            <count group_id="B2" value="1361"/>
            <count group_id="B3" value="1358"/>
            <count group_id="B4" value="4076"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.7" spread="15.05"/>
                    <measurement group_id="B2" value="43.9" spread="15.20"/>
                    <measurement group_id="B3" value="43.3" spread="14.99"/>
                    <measurement group_id="B4" value="43.7" spread="15.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="900"/>
                    <measurement group_id="B2" value="915"/>
                    <measurement group_id="B3" value="902"/>
                    <measurement group_id="B4" value="2717"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="457"/>
                    <measurement group_id="B2" value="446"/>
                    <measurement group_id="B3" value="456"/>
                    <measurement group_id="B4" value="1359"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="278"/>
                    <measurement group_id="B2" value="297"/>
                    <measurement group_id="B3" value="300"/>
                    <measurement group_id="B4" value="875"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1079"/>
                    <measurement group_id="B2" value="1064"/>
                    <measurement group_id="B3" value="1057"/>
                    <measurement group_id="B4" value="3200"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="294"/>
                    <measurement group_id="B2" value="284"/>
                    <measurement group_id="B3" value="244"/>
                    <measurement group_id="B4" value="822"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1025"/>
                    <measurement group_id="B2" value="1037"/>
                    <measurement group_id="B3" value="1078"/>
                    <measurement group_id="B4" value="3140"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Lesion Healing</title>
        <description>Time to complete healing of lesions measured in hours from the time of first dosing</description>
        <time_frame>up to 21 days</time_frame>
        <population>per protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>Test Product</title>
            <description>acyclovir cream: Acyclovir 5 percent (Perrigo)</description>
          </group>
          <group group_id="O2">
            <title>Reference Product</title>
            <description>acyclovir cream: Acyclovir 5 percent (Zovirax)</description>
          </group>
          <group group_id="O3">
            <title>Placebo Product</title>
            <description>vehicle of the test product cream</description>
          </group>
        </group_list>
        <measure>
          <title>Lesion Healing</title>
          <description>Time to complete healing of lesions measured in hours from the time of first dosing</description>
          <population>per protocol population</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="633"/>
                <count group_id="O2" value="652"/>
                <count group_id="O3" value="641"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="107.47" spread="80.660"/>
                    <measurement group_id="O2" value="110.08" spread="82.840"/>
                    <measurement group_id="O3" value="112.41" spread="83.467"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>provides 85% of success</non_inferiority_desc>
            <param_type>Equivalence ratio</param_type>
            <param_value>98.0</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>92</ci_lower_limit>
            <ci_upper_limit>105</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 21 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Test Product</title>
          <description>acyclovir cream&#xD;
Acyclovir 5 percent (Perrigo)</description>
        </group>
        <group group_id="E2">
          <title>Reference Product</title>
          <description>acyclovir cream&#xD;
Acyclovir 5 percent (Reference)</description>
        </group>
        <group group_id="E3">
          <title>Placebo Product</title>
          <description>Placebo cream&#xD;
Placebo cream</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1357"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1361"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1358"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1357"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1361"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1358"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1361"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1358"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Right Forearm Fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1357"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1361"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1358"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1357"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1361"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1358"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Colon Cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1361"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1358"/>
              </event>
              <event>
                <sub_title>Thyroid Cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1361"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1358"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Kidney Stone</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1357"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1361"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1358"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Worsening Of Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1357"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1361"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1358"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1357"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1361"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1358"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jonathan Schwartz</name_or_title>
      <organization>Perrigo</organization>
      <phone>718-960-9900</phone>
      <email>jonathan.schwartz@perrigo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

